Mackay-based clinical research
Coral Sea Clinical Research Institute collaborates with many clinical trial providers as well as biopharmaceutical companies to trial products that can make an enormous difference to the lives of patients suffering from Irritable Bowel Disease and Coeliac Disease.
One of those trial providers, is ImmunsanT - a clinical stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to translate and deliver first-in-class peptide-based immune therapies to patients living with autoimmune diseases.
Currently CSCRI, in conjunction with ImmusanT, are conducting research trials that focus on the Nexvax2 vaccine and Coeliac Disease. The Nexvax2 vaccine is the company’s lead investigational therapeutic vaccine in Coeliac Disease patients who carry the immune recognition genes for HLA-DQ2.5 - a subset that accounts for approximately 90% of those living with the disease.
Nexvax2 is administered as a series of injections and is designed to target and reprogram the T cells that trigger an inflammatory response to gluten. By suppressing this inflammation, it aims to prevent the adverse clinical effects caused by gluten ingestion in people with coeliac disease.